Cited by 217Cytokine Signaling Pathways and InteractionsNF-κB Signaling PathwaysImmune cells in cancer

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Inflammation Amplifier, a New Paradigm in Cancer Biology

Abstract

Tumor-associated inflammation can induce various molecules expressed from the tumors themselves or surrounding cells to create a microenvironment that potentially promotes cancer development. Inflammation, particularly chronic inflammation, is often linked to cancer development, even though its evolutionary role should impair nonself objects including tumors. The inflammation amplifier, a hyperinducer of chemokines in nonimmune cells, is the principal machinery for inflammation and is activated by the simultaneous stimulation of NF-κB and STAT3. We have redefined inflammation as local activation of the inflammation amplifier, which causes an accumulation of various immune cells followed by dysregulation of local homeostasis. Genes related to the inflammation amplifier have been genetically associated with various human inflammatory diseases. Here, we describe how cancer-associated genes, including interleukin (IL)-6, Ptgs2, ErbB1, Gas1, Serpine1, cMyc, and Vegf-α, are strongly enriched in genes related to the amplifier. The inflammation amplifier is activated by the stimulation of cytokines, such as TNF-α, IL-17, and IL-6, resulting in the subsequent expression of various target genes for chemokines and tumor-related genes like BCL2L11, CPNE7, FAS, HIF1-α, IL-1RAP, and SOD2. Thus, we conclude that inflammation does indeed associate with the development of cancer. The identified genes associated with the inflammation amplifier may thus make potential therapeutic targets of can…

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-2322

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 0 references

Research works printed but not linked: 24

  1. Ogura, 2008, Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction, Immunity, 29, 628, 10.1016/j.immuni.2008.07.018 · DOI · Paper page
  2. Lee, 2013, IL-6 amplifier activation in epithelial regions of bronchi after allogeneic lung transplantation, Int Immunol, 25, 319, 10.1093/intimm/dxs158 · DOI
  3. Arima, 2012, Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier, Cell, 148, 447, 10.1016/j.cell.2012.01.022 · DOI · Paper page
  4. Lee, 2012, NFκB-triggered positive-feedback for IL-6 signaling in grafts plays a role for allogeneic rejection responses, J Immunol, 189, 1928, 10.4049/jimmunol.1103613 · DOI
  5. Schmidt, 2007, Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis, EMBO J, 26, 710, 10.1038/sj.emboj.7601539 · DOI
  6. Raychaudhuri, 2010, PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy, PLoS ONE, 5, e15296, 10.1371/journal.pone.0015296 · DOI
  7. Hong, 2006, SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion, Cancer Lett, 236, 39, 10.1016/j.canlet.2005.05.011 · DOI
  8. Adachi, 2006, Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas, Int J Cancer, 119, 1303, 10.1002/ijc.22006 · DOI · Paper page
  9. Dankbar, 2000, Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma, Blood, 95, 2630, 10.1182/blood.V95.8.2630 · DOI
  10. Yi, 2003, The CCL6 chemokine is differentially regulated by c-Myc and L-Myc, and promotes tumorigenesis and metastasis, Cancer Res, 63, 2923
  11. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  12. Colotta, 2009, Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability, Carcinogenesis, 30, 1073, 10.1093/carcin/bgp127 · DOI
  13. de Visser, 2006, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer, 6, 24, 10.1038/nrc1782 · DOI
  14. da Cunha Santos, 2011, EGFR mutations and lung cancer, Annu Rev Pathol, 6, 49, 10.1146/annurev-pathol-011110-130206 · DOI
  15. Chung, 2013, An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy, Nat Med, 19, 1114, 10.1038/nm.3291 · DOI · Paper page
  16. Bassères, 2010, Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis, Cancer Res, 70, 3537, 10.1158/0008-5472.CAN-09-4290 · DOI · Paper page
  17. Roh, 2003, Overexpression of the oncogenic kinase Pim-1 leads to genomic instability, Cancer Res, 63, 8079
  18. Wang, 2006, Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation, Oncogene, 25, 7148, 10.1038/sj.onc.1209707 · DOI
  19. Zhou, 1998, Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation, Nat Genet, 20, 189, 10.1038/2496 · DOI
  20. Felsher, 1999, Transient excess of MYC activity can elicit genomic instability and tumorigenesis, PNAS, 96, 3940, 10.1073/pnas.96.7.3940 · DOI
  21. Silzle, 2004, The fibroblast: sentinel cell and local immune modulator in tumor tissue, Int J Cancer, 108, 173, 10.1002/ijc.11542 · DOI
  22. Llera, 2010, Matricellular proteins and inflammatory cells: a task force to promote or defeat cancer?, Cytokine Growth Factor Rev, 21, 67, 10.1016/j.cytogfr.2009.11.010 · DOI
  23. Ogura, The Gate Theory: how regional neural activation creates a Gateway for immune cells via an inflammation amplifier
  24. Mori, 2013 29, Early pathological alterations of lower lumber cords detected by ultra-high field MRI in a mouse multiple sclerosis model, Int Immunol

Cited by

Sorted by citations

Items 101–193 of 193

Metadata

Authors
Atsumi, T., Singh, R., Sabharwal, L., Bando, H., Meng, J., Arima, Y., Yamada, M., Harada, M., Jiang, J.-J., Kamimura, D., Ogura, H., Hirano, T., & Murakami, M.
Affiliations
Japan Science and Technology Agency (JP)
Venue
Cancer Research
Published
2014-01-01
Volume
74
Issue
1
Pages
8-14
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2101899879
Cited by
217
References
0
Citations by year
2026: 7 · 2025: 13 · 2024: 18 · 2023: 13 · 2022: 16 · 2021: 14 · 2020: 12 · 2019: 18 · 2018: 18 · 2017: 20 · 2016: 20 · 2015: 33 · 2014: 14
FWCI
2.40
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (24790472, 24249028, 26460574, 24390098)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
tumor inflammation, chronic inflammation, carcinogenesis, NF-κB, STAT3, tumor microenvironment, cytokines, interleukin-6, cyclooxygenase-2, EGF receptor, GAS1, SERPINE1, c-Myc, VEGFα, HIF-1α, therapeutic target
MeSH terms
Animals, Humans, Inflammation, Neoplasms, Signal Transduction, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review